Christoph Bausch, PhD

EVP, Chief Operating OfficeratSAB Biotherapeutics· In proxies 2022–2025

Pay in FY2025+41% from the year before · SAB Biotherapeutics stock -1.4% the same year

Christoph Bausch, PhD was paid $1.7M in FY2025 (Dec), up 41%. SAB Biotherapeutics stock fell 1.4% that year.

Pay$100 in the stock at the end of FY21 → $5

Pay is from the Summary Compensation Table of each SAB Biotherapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

SABS
SAB BiotherapeuticsPublic company · 4 yr
- EVP, Chief Operating Officer2022 – Present · 4 yrStock in role -96%

Roles come from the proxy statements of each company.

Activity

Pay
SAB Biotherapeutics COO pay rose 41% to $1.7M. The stock fell 1% in FY2025 (Dec).
DEF 14AApr 30, 2026
Pay
SAB Biotherapeutics COO pay rose 118% to $1.2M. The stock fell 45% in FY2024 (Dec).
DEF 14AJun 2, 2025

For the press:Download CSV Download PNG How to use our data

Two people shown as one, or a wrong number?